If the role of SDF-1 expression would beconfirmed in endometrial cancer patients it could be helpful in designing pharmaceutical trials aimed at the improvement of therapeutic outcomes in SDF-1-positive women. This evidence concerns the gene CXCL12 and endometrial cancer.